Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.

ABSTRACT:

Importance

The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain.

Objective

To assess the effectiveness of montelukast compared with placebo in treating outpatients with mild to moderate COVID-19.

Design, setting, and participants

This randomized clinical trial (Accelerating COVID-19 Therapeutic Interventions and Vaccines [ACTIV]-6) was conducted from January 27 through June 23, 2023, during the circulation of Omicron subvariants. Participants aged 30 years or older with confirmed SARS-CoV-2 infection and 2 or more acute COVID-19 symptoms for less than 7 days were included across 104 US sites.

Interventions

Participants were randomized 1:1 to receive montelukast, 10 mg once daily, or matched placebo

SUBMITTER: Rothman RL 

PROVIDER: S-EPMC11581631 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature